Información del artículo
Resumen
Objetivo
Analizar la correlación entre la expresión de p53, Ki67, bcl-2 y CK20, detectadas por técnicas de inmunohistoquímica, con las variables pronósticas clásicas: grado histológico, estadio clínico y recurrencia del tumor.
Material Y MétodosEstudiamos 57 biopsias de carcinomas transicionales superficiales de vejiga. Las biopsias valoradas correspondían a 36 y 21 carcinomas transicionales de vejiga no recidivantes y recidivantes, respectivamente. Determinados la correlación entre la expresión de p53, Ki-67, bcl-2 y CK20 con el estadio clínico, grado histológico y la recurrencia del tumor.
ResultadosDemostramos una correlación estadísticamente significativa entre la expresión de Ki-67 y p53 con el grado histológico y la recidiva del tumor. No demostramos asociación estadísticamente significativa entre la expresión de bcl-2 y CK20 con el grado histológico, estadio clínico y recurrencia del tumor.
ConclusionesLa expresión de p53 y Ki-67 aumenta conforme aumenta el grado histológico del tumor y permite predecir la recurrencia de los carcinomas transicionales superficiales de vejiga.
Palabras Clave:
Carcinoma transicional superficial
Vejiga
Proteína p53
Ki-67
bcl-2
CK20
Abstract
Objetivo
Analizar la correlación entre la expresión de p53, Ki67, bcl-2 y CK20, detectadas por técnicas de inmunohistoquímica, con las variables pronósticas clásicas: grado histológico, estadio clínico y recurrencia del tumor.
Material Y MétodosEstudiamos 57 biopsias de carcinomas transicionales superficiales de vejiga. Las biopsias valoradas correspondían a 36 y 21 carcinomas transicionales de vejiga no recidivantes y recidivantes, respectivamente. Determinados la correlación entre la expresión de p53, Ki-67, bcl-2 y CK20 con el estadio clínico, grado histológico y la recurrencia del tumor.
ResultadosDemostramos una correlación estadísticamente significativa entre la expresión de Ki-67 y p53 con el grado histológico y la recidiva del tumor. No demostramos asociación estadísticamente significativa entre la expresión de bcl-2 y CK20 con el grado histológico, estadio clínico y recurrencia del tumor.
ConclusionesLa expresión de p53 y Ki-67 aumenta conforme aumenta el grado histológico del tumor y permite predecir la recurrencia de los carcinomas transicionales superficiales de vejiga.
Key Works:
Transitional cell carcinoma
Bladder
p53 protein
Ki-67
bcl-2
CK20
El Texto completo está disponible en PDF
Referencias
[1.]
S.M. Cohen, L.B. Ellwein.
Cell proliferation and bladder tumorpromotion.
Prog Clin Biol Res, 369 (1991), pp. 347-355
[2.]
R.T. Vollmer, P.A. Humphrey, P.E. Swanson, et al.
Invasión of the bladder by transitional cell carcinoma: its relation to histologic grade and expresión of p53, MIB-1, cerbB2, epidermal growth factor receptor and bcl-2.
Cancer, 82 (1998), pp. 715-723
[3.]
H. Tsujihashi, A. Nakanishi, H. Matsuda, et al.
Cell proliferation of human bladder tumors determined by brdurd and ki-67 immunostaining.
J Urol, 145 (1991), pp. 846-849
[4.]
T.T. Wu, J.H. Chen, Y.X. Lee, J.K. Huang.
The role of bcl-2, p53 and Ki67 index in predicting tumor recurrence for low grade superficial transitional cell bladder carcinoma.
J Urol, 163 (2000), pp. 758-760
[5.]
L. Nakopoulou, C. Vourlakou, A. Zervas, A. Tzonou, H. Gakiopoulou, M.A. Dimopoulos.
The prevalence of bcl-2, p53 and ki67 immunoreactivity in transitional cell bladder carcinomas and their clinicopathologiccorrelates.
Hum Pathol, 29 (1998), pp. 146-154
[6.]
B. Li, H. Kanamaru, S. Noriki, T. Yamaguchi, M. Fukuda, K. Okada.
Reciprocal expression of bcl- 2 and p53 oncoproteins in urothelial dysplasia and carcinoma of the urinarybladder.
Urol Res, 26 (1998), pp. 235-241
[7.]
P.K. Lipponen, S. Aaltomaa, M. Eskelinen.
Expression of the apoptosis suppressing bcl-2 protein in transitional cell bladdertumours.
Histopathology, 28 (1996), pp. 135-140
[8.]
F. Atug, L. Turkeri, M. Ozyurek, et al.
Bcl-2 and p53 overexpression as associated risk factors in transitional cell carcinoma of thebladder.
Int Urol Nephrol, 30 (1998), pp. 455-461
[9.]
E.J. Kirsh, D.A. Baunoch, W.M. Stadler.
Expression of bcl-2 and bcl-x in bladder cancer.
JUrol, 159 (1998), pp. 1348-1353
[10.]
T.J. Liukkonen, P.K. Lipponen, M. Helle, K.E. Jauhiainen.
Immunoreactivity of bcl-2, p53, and egfr is associated with tumor stage, grade and cell proliferationin superficial bladdercancer.finnbladder iii group.
Urol Res, 25 (1997), pp. 1-7
[11.]
S.H. Glick, L.P. Howell, R.W. Devere White.
Relationship of p53 and bcl-2 to prognosis in muscle- invasive transitional cell carcinoma of the bladder.
J Urol, 155 (1996), pp. 1754-1757
[12.]
P.K. Lipponen.
Overexpression of p53 nuclear oncoprotein in transitional cell bladder cancer and its prognosticvalue.
Int I Cancer, 53 (1993), pp. 365-370
[13.]
G. Dalbagni, J.C. Presti Jr., V.E. Reuter, et al.
Molecular genetic alterations of chromosome 17 and p53 nuclear overexpression in human bladdercancer.
Diag Mol Pathol, 2 (1993), pp. 4-13
[14.]
T. Inagaki, S. Ebisuro, Y. Uekado, et al.
Pcna and p53 in urinary bladder cancer: correlation with histological findings andprognosis.
Int J Urol, 4 (1997), pp. 172-177
[15.]
C. Cordón-cardó, Z.F. Zhang, G. Dalbagni, et al.
Cooperative effects of p53 and prb alterations in primary superficial bladdertumors.
Cancer Res, 57 (1997), pp. 1217-1221
[16.]
B.J. Schmitz-Drager, M. Kushima, P. Goebell, et al.
p53 and MDM2 in the development and progression of bladdercancer.
Eur Urol, 32 (1997), pp. 487-493
[17.]
A. Rodríguez-Alonso, S. Pita-Fernández, J. González-Carreró, J.L. Nogueira-March.
Multivariate análisis of survival, recurrence, progresión and development of metastasis in T1 and T2a transicional cell bladdercarcinoma.
Cancer, 94 (2002), pp. 1677-1984
[18.]
J.L. Moyano Calvo, M. De Miguel Rodriguez, A. Ortiz Gamiz, et al.
Determinación de ploidía de Adn mediante citometría de flujo, índice Ki-67 y sobre-expresión p53 en 121 carcinomas superficiales de vejiga T1. Estudio retrospectivo correlación con las variables clásicas.
Actas Urol Esp, 24 (2000), pp. 785-795
[19.]
E.N. Strouopoulos, E. Ioackim-Velogianni, K. Hastazeis, et al.
Growth fractions in bladder cancer defined by ki-67 expression, and nuclear organiser regions.
JClin Pathol, 46 (1993), pp. 159-165
[20.]
K. Okamura, K. Miyake, T. Koshikawa, et al.
Growth fractions of transitional cell carcinomas of the bladder defined by the monoclonal antibody ki- 67.
J Urol, 144 (1990), pp. 875-878
[21.]
S. Krüger, H. Müller.
Correlation of morphometry nucleolar organizer regions, proliferating cell nuclear antigen and ki-67 antigen expression with grading and staging in urinary bladdercarcinomas.
Br J Urol, 75 (1995), pp. 480-484
[22.]
A.H. Mulders, J.C. Van Hootegem, et al.
Prognostic factors as in bladder carcinoma: histological parameters and expression of a cycle-related nuclear antigen Ki-67.
JPathol, 166 (1992), pp. 37-43
[23.]
C. Pfister, F. Buzelin, C. Cvasse, et al.
Comparative analysis of MIB-1 and p53 expression in human bladder tumours and their correlation with cancerprogression.
Eur Urol, 33 (1998), pp. 278-284
[24.]
C. Limas, A. Bigler, R. Bair, et al.
Proliferative activity of urothelial neoplasms: comparison of BrDU incorporation, Ki-67: association with cancer grade, category and recurrence rate of superficiallesions.
Br J Urol, 72 (1993), pp. 736-739
[25.]
P. Chu, E. Wu, L.M. Weiss.
Cytokeratin 7 and 20 expression in epithelial neoplasms: a survey of 435cases.
Mod Pathol, 13 (2000), pp. 962-972
[26.]
J. Southgate, P. Harnden, L.K. Trejdosiewicz.
Cytokeratin expression patterns in normal and malignant urothelium: a review of the biological and diagnosticimplications.
Histol Histopathol, 14 (1999), pp. 657-664
[27.]
P. Harnden, N. Mahmood, J. Southgate.
Expression of cytokeratin 20 redefines urothelial papillomas of thebladder.
Lancet, 353 (1999), pp. 974-977
[28.]
G. Cattoretti, M.H.G Becker, G. Key, et al.
Monoclonal antibodies organist recombinant parts of the ki-67 antigen detected proliferatig cells in microwave-processed formalin-fixed paraffin sections.
J Pathol, 168 (1992), pp. 357-363
[29.]
G.B. Bartetton, J. Diebold, G. Christoforis, et al.
Apoptosis and immunohistochemical bcl-2 expression in colorectal adenomas andcarcinomas.
Cancer, 77 (1996), pp. 255-264
[30.]
S. Pilotti, P. Collini, F. Rilke, et al.
Bcl-2 protein expression in carcinomas originating from the follicular epithelium of the thyroid gland.
J Pathol, 172 (1994), pp. 337-342
[31.]
M.E.J.M Verhaegh, C.J.G Sanders, J.W. Arends, et al.
Expression of the apoptosis-suppressing protein bcl-2 in non-melanoma skincancer.
Br J Dermatol, 132 (1995), pp. 740-744
[32.]
J. Álvarez Kindelán, A. López-Beltrán, M.J. Requena Tapia.
Biología molecular en el cáncervesical.
Actas Urol Esp, 24 (2000), pp. 604-625
[33.]
F.C. Burkhard, R. Markwalder, G.N. Thalmann, U.E. Studer.
Inmunohistochemical determination of p53 expression.
Urol Res, 25 (1997), pp. S31-S35
[34.]
M. Caliskan, L.N. Turkeri, B. Mansuroglu, et al.
Nuclear accumulation of mutant p53 protein: a possible predictor of failure of intravesical therapy in bladder cancer.
Br J Urol, 79 (1997), pp. 373-377
[35.]
D. Esrig, D. Elmajian, S. Groshen, et al.
Accumulation of nuclear p53 and tumor progression in bladder cancer.
New Engl J Med, 331 (1994), pp. 1259-1264
[36.]
Z. Sinik, T. Alkibay, O. Ataoglu, et al.
Correlation of nuclear p53 overexpression with clinical and histopathological features of transitional cell bladder cancer.
Int Urol Nephrol, 29 (1997), pp. 25-31
[37.]
D. Ye, H. Li, S. Quian, Y. Sun, J. Zheng, Y. Ma.
Bcl 2/bax expression and p53 gene status in human bladder cancer: relationship to early recurrence with intravesical quemotherapy after resection.
J Urol, 160 (1998), pp. 2025-2029
[38.]
K.S. Chandhary, Q.L. Lu, P.D. Abel, et al.
Expresión of bcl-2 and p53 oncoproteins inschistosomiasis associated transitional and squamous cell carcinoma of urinary bladder.
Br J Urol, 79 (1997), pp. 78-84
[39.]
U. Wagner, G. Sauter, H. Moch, et al.
Patterns of p53, erb-2 and egf-r expression in premalignant lesions of the urinary bladder.
Hum Pathol, 9 (1995), pp. 970-978
[40.]
A.R. Zlotta, J.C. Noel, I. Fayt, et al.
Correlation and prognostic significance of p53, p21waf1/cip1 and ki-67 expression in patients with superficial bladder tumors treated with bacillus calmette- guérin intravesical therapy.
J Urol, 161 (1999), pp. 792-798
[41.]
C. Pfister, L. Lacombe, M.C. Vezina, et al.
Prognostic value of the proliferative index determined by Ki-67 immunostaining in superficial bladder tumors.
Hum Pathol, 30 (1999), pp. 1350-1355
[42.]
P. Harnen, N. Mahmood, J. Southgate.
Expression of cytokeratin 20 redefines urothelial papillomas of the bladder.
Lancet, 353 (1990), pp. 974-977
[43.]
A. Alsheikh, Z. Mohamedali, E. Jones, J. Masterson, C.B. Gilks.
Comparison of the WHO/ISUP classification and cytokeratin 20 expression in predicting the behaviour of low-grade papillary urothelial tumors. world/health organization /international society of urologic pathology.
Mod Pathol, 14 (2002), pp. 267-272
Copyright © 2003. Asociación Española de Urología (AEU)
